Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine (NASDAQ:EDIT) Inc on Friday, setting a price target of $55, which is approximately 100.07% above the present share price of $27.49.
Livshits expects Editas Medicine Inc to post earnings per share (EPS) of -$0.69 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Hold rating of shares in Editas Medicine, with an average price target of $28.5.
The analysts price targets range from a high of $30 to a low of $27.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $5.72 million and a net profit of -$46.62 million. The company's market cap is $1.37 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.0% and a 64.56% success rate.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.